These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 20974126)
1. Stemness markers characterize IGR-CaP1, a new cell line derived from primary epithelial prostate cancer. Chauchereau A; Al Nakouzi N; Gaudin C; Le Moulec S; Compagno D; Auger N; Bénard J; Opolon P; Rozet F; Validire P; Fromont G; Fizazi K Exp Cell Res; 2011 Feb; 317(3):262-75. PubMed ID: 20974126 [TBL] [Abstract][Full Text] [Related]
2. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer. Navone NM; Rodriquez-Vargas MC; Benedict WF; Troncoso P; McDonnell TJ; Zhou JH; Luthra R; Logothetis CJ Clin Cancer Res; 2000 Mar; 6(3):1190-7. PubMed ID: 10741751 [TBL] [Abstract][Full Text] [Related]
3. A novel neoplastic primary tumor-derived human prostate epithelial cell line. Ko D; Gu Y; Yasunaga Y; Nakamura K; Srivastava S; Moul JW; Sesterhenn IA; McLeod DG; Arnstein P; Taylor DO; Hukku B; Rhim JS Int J Oncol; 2003 Jun; 22(6):1311-7. PubMed ID: 12738999 [TBL] [Abstract][Full Text] [Related]
4. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Navone NM; Olive M; Ozen M; Davis R; Troncoso P; Tu SM; Johnston D; Pollack A; Pathak S; von Eschenbach AC; Logothetis CJ Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2493-500. PubMed ID: 9815652 [TBL] [Abstract][Full Text] [Related]
5. Primary prostate cancer cultures are models for androgen-independent transit amplifying cells. Bühler P; Wolf P; Katzenwadel A; Schultze-Seemann W; Wetterauer U; Freudenberg N; Elsässer-Beile U Oncol Rep; 2010 Feb; 23(2):465-70. PubMed ID: 20043108 [TBL] [Abstract][Full Text] [Related]
6. Human prostate cancer progression models and therapeutic intervention. Chung LW; Kao C; Sikes RA; Zhau HE Hinyokika Kiyo; 1997 Nov; 43(11):815-20. PubMed ID: 9436028 [TBL] [Abstract][Full Text] [Related]
7. Selection of cell lines with enhanced invasive phenotype from xenografts of the human prostate cancer cell line WPE1-NB26. Rivette AS; Tokar EJ; Williams DE; Mackenzie CD; Ablin RJ; Webber MM J Exp Ther Oncol; 2005; 5(2):111-23. PubMed ID: 16471037 [TBL] [Abstract][Full Text] [Related]
8. A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice. Sato N; Gleave ME; Bruchovsky N; Rennie PS; Beraldi E; Sullivan LD Cancer Res; 1997 Apr; 57(8):1584-9. PubMed ID: 9108464 [TBL] [Abstract][Full Text] [Related]
9. Expression of adrenomedullin and peptide amidation activity in human prostate cancer and in human prostate cancer cell lines. Rocchi P; Boudouresque F; Zamora AJ; Muracciole X; Lechevallier E; Martin PM; Ouafik L Cancer Res; 2001 Feb; 61(3):1196-206. PubMed ID: 11221851 [TBL] [Abstract][Full Text] [Related]
10. Epithelial and prostatic marker expression in short-term primary cultures of human prostate tissue samples. Festuccia C; Angelucci A; Gravina GL; Muzi P; Miano R; Vicentini C; Bologna M Int J Oncol; 2005 May; 26(5):1353-62. PubMed ID: 15809728 [TBL] [Abstract][Full Text] [Related]
12. A telomerase-immortalized primary human prostate cancer clonal cell line with neoplastic phenotypes. Gu Y; Kim KH; Ko D; Nakamura K; Yasunaga Y; Moul JW; Srivastava S; Arnstein P; Rhim JS Int J Oncol; 2004 Oct; 25(4):1057-64. PubMed ID: 15375556 [TBL] [Abstract][Full Text] [Related]
13. Stem/progenitor and intermediate cell types and the origin of human prostate cancer. Tokar EJ; Ancrile BB; Cunha GR; Webber MM Differentiation; 2005 Dec; 73(9-10):463-73. PubMed ID: 16351690 [TBL] [Abstract][Full Text] [Related]
14. Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells. Patrawala L; Calhoun-Davis T; Schneider-Broussard R; Tang DG Cancer Res; 2007 Jul; 67(14):6796-805. PubMed ID: 17638891 [TBL] [Abstract][Full Text] [Related]
15. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells. Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142 [TBL] [Abstract][Full Text] [Related]
17. A novel human cancer culture model for the study of prostate cancer. Yasunaga Y; Nakamura K; Ko D; Srivastava S; Moul JW; Sesterhenn IA; McLeod DG; Rhim JS Oncogene; 2001 Nov; 20(55):8036-41. PubMed ID: 11753687 [TBL] [Abstract][Full Text] [Related]
18. Human cell lines as an in vitro/in vivo model for prostate carcinogenesis and progression. Webber MM; Quader ST; Kleinman HK; Bello-DeOcampo D; Storto PD; Bice G; DeMendonca-Calaca W; Williams DE Prostate; 2001 Apr; 47(1):1-13. PubMed ID: 11304724 [TBL] [Abstract][Full Text] [Related]
19. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Raffo AJ; Perlman H; Chen MW; Day ML; Streitman JS; Buttyan R Cancer Res; 1995 Oct; 55(19):4438-45. PubMed ID: 7671257 [TBL] [Abstract][Full Text] [Related]
20. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. Nemeth JA; Harb JF; Barroso U; He Z; Grignon DJ; Cher ML Cancer Res; 1999 Apr; 59(8):1987-93. PubMed ID: 10213511 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]